B. Riley Research Analysts Cut Earnings Estimates for Harrow

Harrow, Inc. (NASDAQ:HROW) – Equities researchers at B. Riley cut their Q4 2025 earnings estimates for Harrow in a research note issued to investors on Tuesday, September 30th. B. Riley analyst M. Mamtani now expects that the company will earn $0.55 per share for the quarter, down from their previous estimate of $0.63. B. Riley currently has a “Buy” rating and a $74.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share.

Harrow (NASDAQ:HROW) last announced its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.23. The business had revenue of $63.74 million during the quarter, compared to analyst estimates of $64.23 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. Harrow has set its FY 2025 guidance at EPS.

HROW has been the topic of a number of other research reports. Zacks Research downgraded Harrow from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 12th. BTIG Research reiterated a “buy” rating and set a $63.00 price objective on shares of Harrow in a research report on Wednesday, September 24th. Cantor Fitzgerald initiated coverage on Harrow in a report on Friday, July 11th. They set an “overweight” rating and a $76.00 price objective on the stock. William Blair initiated coverage on Harrow in a research report on Tuesday, June 10th. They issued an “outperform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $64.00 price target on shares of Harrow in a research report on Monday. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $68.50.

Harrow Stock Performance

NASDAQ HROW opened at $47.73 on Thursday. Harrow has a 52-week low of $20.85 and a 52-week high of $59.23. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. The company has a market capitalization of $1.77 billion, a P/E ratio of -190.92 and a beta of 0.27. The company has a fifty day moving average of $39.38 and a 200-day moving average of $32.07.

Hedge Funds Weigh In On Harrow

A number of large investors have recently bought and sold shares of HROW. Quarry LP bought a new stake in Harrow in the first quarter valued at approximately $32,000. Raymond James Financial Inc. purchased a new position in shares of Harrow in the second quarter worth $48,000. Tower Research Capital LLC TRC increased its stake in shares of Harrow by 345.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after buying an additional 2,615 shares during the period. State of Wyoming bought a new stake in Harrow during the 1st quarter valued at $97,000. Finally, Strs Ohio purchased a new stake in Harrow during the 1st quarter valued at $149,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.